Abstract 467P
Background
Lung cancer is a serious problem and one of the most common cancer diseases worldwide. Many studies were shown that free-circulating mtDNA levels are increased in the serum/plasma of patients with various malignancies. Here we analysed mtDNA levels in the plasma of patients with NSCLC compared to the health individuals.
Methods
68 patients with NSCLC and 59 healthy individuals were recruited for this study. A quantitative analysis of the free-circulating mtDNA was conducted using the qPCR. To create a standard curve, the purified PCR product of the 490 bp mtDNA fragment was used. The DNA concentration determined using the PicoGreen dsDNA Quantification Kit. The copy number of the free-circulating mtDNA was calculated according to the protocol of Applied Biosystems.
Results
The levels of free-circulating mtDNA in patients with NSCLC were found in range from 2.7x1010 to 6,51x1014 with a mean value 3,04x1013 copies/μL. In plasma samples of healthy subjects the levels of mtDNA copies were found to range from 6,0x109 to 1,73x1013 with a mean value 7,46x1011. Thus, the levels of free-circulating mtDNA in patients with NSCLC were higher in 6.6 times than in those of healthy subjects (P < 0.05).
Conclusions
Results of this study suggest that high free-circulating mtDNA copies number is a promising marker for diagnosis and prediction of non-small cell lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Authors.
Funding
Ministry of Education and Science of the Republic of Kazakhstan (grant no. 1258/GF4).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - NOTCH3 expression predicts poor survival in advanced esophageal squamous cell cancers
Presenter: Raja Pramanik
Session: Poster display session
Resources:
Abstract
144P - Severe hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial
Presenter: Radka Obermannova
Session: Poster display session
Resources:
Abstract
145P - Role of Glasgow prognostic score in chemo-naïve patients with advanced biliary tract cancer and good performance status
Presenter: Toshikazu Moriwaki
Session: Poster display session
Resources:
Abstract
146P - Anatomic versus non-anatomic resection for hepatocellular carcinoma: A meta-analysis of high-quality studies
Presenter: Bin Zhang
Session: Poster display session
Resources:
Abstract
147P - Clinical outcomes of proximal gastrectomy versus total gastrectomy for locally advanced proximal gastric cancer: a propensity score matching analysis
Presenter: Yingtai Chen
Session: Poster display session
Resources:
Abstract
148P - Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage
Presenter: Seunghwan Lee
Session: Poster display session
Resources:
Abstract
150P - A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
Presenter: Yee Chao
Session: Poster display session
Resources:
Abstract
151P - Gene expression profiling for a better understanding of gastric cancer: From the perspective of metabolic rearrangement
Presenter: Midie Xu
Session: Poster display session
Resources:
Abstract
152P - Long-term outcomes of three-dimensional conformal radiotherapy-based and intensity-modulated radiotherapy-based concurrent chemoradiotherapy in patients with thoracic esophageal squamous cell carcinoma
Presenter: Chia-Lun Chang
Session: Poster display session
Resources:
Abstract
153P - Exosomal LINC00174 facilitates epithelial-mesenchymal transition in residual hepatocellular carcinoma after insufficient radiofrequency ablation by regulating c-JUN/MYCBP/c-Myc axis
Presenter: Dening Ma
Session: Poster display session
Resources:
Abstract